New paper lays out problems of developing gene-edited GM crops
By Claire Robinson,
GM Watch
| 08. 30. 2023
Announcing the passing into law of the Genetic Technology Act, which removes regulatory safeguards around a whole subclass of GMOs, notably those produced using gene editing, the Westminster government breathlessly enthused that the UK had now joined “Argentina, the US, Australia and Japan”, which “have already enacted similar legislation, driving innovation on a global scale and helping fight the greatest challenges facing the world”.
I can’t pretend that GMWatch was waiting with bated breath for the “new GM”-based “innovation on a global scale” that was supposed to be pouring out of these countries, especially given the dismal performance and fate of the handful of gene-edited crops that they've released.
But the history of GM crops has settled into a pattern of hyped reports of supposed successes continuing for a good few years before they give way to sad tales of technology failure. So at this early stage of the “new GM” journey, we were expecting something reasonably upbeat about gene-edited GM crops from these deregulatory pioneering countries.
What we didn’t expect just yet is the catalogue of abject failure...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...